SEEL earnings
Seelos Therapeutics Inc. (SEEL) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease-A single dose of SLS-004 produced a substantial increase in recovery of tyrosine hydroxylase-positive (TH+) dopaminergic neurons that are known to degenerate in patients with Parkinson's disease -Degeneration of TH+ midbrain dopaminergic neurons in patients with Parkinson's disease is attributed to lead to the cardinal Parkinsonian symptoms of tremor, rigidity, bradykinesia and postural disturbances -Seelos management will discuss additional information about this study during the Research and Development Update Conference Call and Webcast today, December 15th at 1pm ET NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical compan
- Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022NEW YORK, Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15th from 1pm to 3pm ET. Registration is available at https://lifescievents.com/event/seelos-therapeutics-kol-event/, and https://seelostherapeutics.com/registration-for-12-15-rd-update-webcast/. Itinerary for the Research and Develo
- Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022NEW YORK, Nov. 23, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET. "As we approach, what we believe to be, a very important and catalyst heavy 2023 for Seelos, it is important that we update our investors about our progress and strategic plans," said Raj Mehra Ph.D., Chairman and CEO